LIPI- PROTECT-2 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP2) (LPP2)
Effect of the Dietary Supplement LIPI-PROTECT-2 on Plasma LDL Cholesterol Concentration in Subjects With Moderate Hypercholesterolemia: A Pilot Study.
This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-2.The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.LIPI-PROTECT-2 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-2 in adults with untreated moderate hypercholesterolemia.A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-2 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.The primary objective is to assess the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.Secondary objectives are to evaluate the effect of LIPI-PROTECT-2 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Coralie BERTHIER, PhD
- Numer telefonu: +33 0320877333
- E-mail: coralie.berthier@pasteur-lille.fr
Kopia zapasowa kontaktu do badania
- Nazwa: Frédéric BATTEUX, MD
- Numer telefonu: +33 320877316
- E-mail: frederic.batteux@pasteur-lille.fr
Lokalizacje studiów
-
-
Nord
-
Lille, Nord, Francja, 59019
- Rekrutacyjny
- Prevention research center - Institut Pasteur of Lille
-
Kontakt:
- Coralie BERTHIER, PhD
- Numer telefonu: +33 0320877333
- E-mail: coralie.berthier@pasteur-lille.fr
-
Kontakt:
- Bérengère LEGENDRE
- Numer telefonu: +33 0320877346
- E-mail: berengere.legendre@pasteur-lille.fr
-
Główny śledczy:
- Frédéric BATTEUX, MD
-
-
Vaucluse
-
Avignon, Vaucluse, Francja, 84140
- Rekrutacyjny
- Biophysium Avignon
-
Kontakt:
- Gaetan BOLEA, PhD
- Numer telefonu: +33 0660663995
- E-mail: g.bolea@biophysium.com
-
Kontakt:
- Romain CAYUELA, MD
- Numer telefonu: +33 0629355794
- E-mail: docteur.cayuelaromain@gmail.com
-
Główny śledczy:
- Romain CAYUELA, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Men and women aged 18-65 years For women :If pre-menopausal: effective non-estrogenic* contraception initiated at least 2 cycles prior and maintained throughout the studyIf post-menopausal: not receiving estrogenic* Hormone Replacement Therapy (HRT)
- LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
- Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
- BMI between 20 and 35 kg/m² (inclusive)
- Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
- Willing to comply with study requirements
- Signed informed consent
Exclusion Criteria:
- Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
- Subjects with triglyceride levels > 4 g/L
- Subjects requiring immediate lipid-lowering therapy
- Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
- Subjects receiving beta-blockers and/or diuretics
- Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
- Subjects receiving anticoagulant therapy
- Subjects receiving antiretroviral therapy
- Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
- Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function)
- Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
- Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active malignancy, hematological disease)
- Subjects with an allergy to any of the components of LIPI-PROTECT-2 Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
- Subjects participating in another clinical study or currently within the exclusion period of another study
- Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Food supplement group
Three tablets of LIPI-PROTECT-2 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers |
All subjects will consume 4 capsules per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 2 capsules in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 capsules in the evening during dinner. If a dose is missed, 1 capsule can be taken at the next dose |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
Ramy czasowe: To baseline at 3 months
|
To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3). |
To baseline at 3 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
Ramy czasowe: To baseline at 3 months
|
To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3). |
To baseline at 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on LDL cholesterol.
Ramy czasowe: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on Non HDL cholesterol.
Ramy czasowe: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on total cholesterol.
Ramy czasowe: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on HDL cholesterol.
Ramy czasowe: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on triglycerides.
Ramy czasowe: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on non HDL cholesterol/LDL (atherogenic index).
Ramy czasowe: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on ratio LDL/HDL.
Ramy czasowe: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on ratio total cholesterol/HDL.
Ramy czasowe: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on fasting blood glucose levels.
Ramy czasowe: At baseline, 1 month and 3 months
|
Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3 |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on weight.
Ramy czasowe: At baseline, 1 month and 3 months
|
Changes in weight (unit : kilograms) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on Body Mass Index (BMI).
Ramy czasowe: At baseline, 1 month and 3 months
|
Changes in BMI (weight and height will be combined to report BMI) in kg/m^2between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on waist circumference.
Ramy czasowe: At baseline, 1 month and 3 months
|
Changes in waist circumference (unit: cm) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on arterial blood pressure
Ramy czasowe: At baseline, 1 month and 3 months
|
Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on heart rate
Ramy czasowe: At baseline, 1 month and 3 months
|
Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism: ASAT/ALAT, GGT
Ramy czasowe: At baseline and 3 months
|
Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 . |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism : Creatinine, bilirubin
Ramy czasowe: At baseline and 3 months
|
Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Urea
Ramy czasowe: At baseline and 3 months
|
Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Creatinine Phophoskinase (CPK)
Ramy czasowe: At baseline and 3 months
|
Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on Renal metabolism : Lactate Deshydrogenase (LDH)
Ramy czasowe: At baseline and 3 months
|
Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3. |
At baseline and 3 months
|
|
To assess adherence to LIPI-PROTECT-2 consumption by pillbox weighing
Ramy czasowe: At baseline, 1 month and 3 months
|
Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0). |
At baseline, 1 month and 3 months
|
|
To assess self-reported adherence to LIPI-PROTECT-2 consumption
Ramy czasowe: At baseline, 1 month, 2 months and 3 months
|
Adherence assessed through participant self-reporting of supplement consumption and missed doses. |
At baseline, 1 month, 2 months and 3 months
|
|
To assess adherence to LIPI-PROTECT-2 consumption by counting returned tablets
Ramy czasowe: At 3 months
|
Adherence assessed by counting the remaining tablets returned by participants at the end of the study. |
At 3 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Krzesło do nauki: Coralie BERTHIER, PhD, Institut Pasteur of Lille
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Metabolizm, Wrodzone Błędy
- Choroby genetyczne, wrodzone
- Choroby metaboliczne
- Hiperlipidemie
- Dyslipidemie
- Zaburzenia metabolizmu lipidów
- Metabolizm lipidów, błędy wrodzone
- Hiperlipoproteinemie
- Wrodzone, dziedziczne i noworodkowe choroby i nieprawidłowości
- Choroby żywieniowe i metaboliczne
- Hipercholesterolemia
- Hiperlipoproteinemia typu II
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 2026-A00950-51
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .